Xeris anticipates exceeding the guidance range with a total revenue of $292 million for full-year 2025, showing a 44% growth compared to the prior year.
The company expects fourth quarter and full-year 2025 Recorlev ® net revenue to reach $45 million and $139 million, respectively.
Xeris announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, highlighting the exceptional performance of Recorlev ® and overall growth.
Revenue Exceeds Expectations
Xeris anticipates total revenue of approximately $292 million for 2025, surpassing the high end of the full-year guidance.
Product Performance
Recorlev ® showed exceptional results, surpassing expectations and contributing significantly to the revenue growth.
Strategic Outlook
Xeris enters 2026 with strong commercial momentum, a robust balance sheet, and clear strategies for sustained growth.
Commercial Expansion
The company executed its commercial expansion plan as intended, with positive Adjusted EBITDA in every quarter.
Intellectual Property Strengthened
Xeris enhanced its intellectual property portfolio with new patents, positioning for long-term protection across commercial and pipeline assets.
- Xeris delivered remarkable financial results for full-year 2025, showcasing a robust growth trajectory and outperforming expectations.
- The positive performance of key products like Recorlev ®, Gvoke ®, and Keveyis ® contributed significantly to the total revenue exceeding the guidance range.
- The company's strategic vision, combined with new patents and commercial momentum, sets a promising outlook for sustained growth and value creation in 2026.
Xeris Biopharma Holdings, Inc. concludes with strong financial results for 2025 and a positive outlook for 2026, driven by product performance and strategic initiatives.